Regulation of matrix metalloproteinase-13 in cancer: Signaling pathways and non-coding RNAs in tumor progression and therapeutic targeting

Figure 5 Involvement of long non-coding RNAs in regulating matrix metalloproteinase-13 expression in cancer. This figure illustrates the role of long non-coding RNAs in regulating matrix metalloproteinase-13 expression across various cancer types. LncRNAs: Long non-coding RNAs; MMP: Matrix metalloproteinase; LAD: Lung adenocarcinoma; ESCC: Esophageal squamous cell carcinoma; TNBC: Triple negative breast cancer; CSCC: Cutaneous squamous cell carcinoma; RCC: Renal cell carcinoma; OSCC: Oral squamous cell carcinoma; HSP90B: Heat shock protein-90 beta; LAMC2: Laminin subunit gamma 2; PTTG1: Pituitary tumor transforming gene 1; RUNX2: Runt-related transcription factor 2; TGF-β1: Transforming growth factor beta 1; AR: Androgen receptor; ECRG4: Esophageal cancer related gene 4; EMT: Epithelial mesenchymal transition; MALAT1: Metastasis associated lung adenocarcinoma transcript 1; CASC9: Cancer susceptibility candidate 9; CCAT2: Colon cancer associated transcript 2; GPAND: Gastric progression associated non-coding RNA; PCAT7: Prostate cancer-associated transcript 7; SNHG12: Small nucleolar RNA host gene 12; SARCC: Suppressing androgen receptor in renal cell carcinoma; NNT-AS1: Nicotinamide nucleotide transhydrogenase antisense RNA 1; HCG11: Human leukocyte antigen complex group 11; FAK: Focal adhesion kinase; P13K: Phosphoinositide 3-kinase; Akt: Protein kinase B.